BioXcel Therapeutics Inc
BTAI - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$902.17K
Close$
$-1.08
1564.5% downside
Current Fair Value
1564.5% downsideOvervalued by 1564.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $902,171.00 |
|---|---|
| Enterprise Value | $92.51 Million |
| Earnings per Share | $-5.73 |
| Beta | 0.29 |
| Outstanding Shares | 12,208,000 |
Return
| Return on Equity | 61.37% |
|---|---|
| Return on Assets | -246.05% |
| Return on Invested Capital | 52.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | -0.01 |
| Enterprise Value to Revenue | 124.68 |
| Enterprise Value to EBIT | -1.63 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 1.13 |
| Debt to Equity | -0.9 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.44
Consensus analyst estimateRevenue Estimate
$484,630
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-1.01
Consensus analyst estimateRevenue Estimate
$191,394
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 50.59%▲ 6.02% |
|---|---|
| Total Invested | $8.69M▲ 19.38% |
| Investors Holding | 48▲ 8.00% |
About BioXcel Therapeutics Inc
29 employees
CEO: Vimal Mehta
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in th...